TransEnterix (NYSE:TRXC) announced today that it has won a CE Mark for an expanded indication to treat children above 10 kg (22 lb) with the Senhance robotic surgery system.
“Given the size of the patients, pediatric surgery seeks to use the smallest instruments and scopes possible to minimize invasiveness, yet it is critical to maintain a high degree of precision,” TransEnterix CEO Anthony Fernando said in a news release.
“The Senhance System is designed to maximize control of instruments as small as 3 mm and be compatible with small scopes while also retaining the sense of touch through haptic feedback. This makes our technology uniquely positioned to meet the requirements of pediatric surgeons, and we look forward to working closely with leading European hospitals to serve the needs of their pediatric patients,” Fernando said.
Dr. Wim van Gemert, chair of the pediatric surgery department at Maastricht University Medical Center+ in the Netherlands, said it is exciting to have the ability to use 3 mm microlaparoscopic instruments on a robotic platform.
“Especially in younger patients, smaller ports and instruments are critically important in achieving the best outcomes given the body size constraints in these patients,” van Gemert said.
Research Triangle Park, N.C.– based TransEnterix touts its Senhance System as a more economical option when it comes to laparoscopic and robotic systems, with haptic feedback, surgeon camera control via eye sensing and improved ergonomics. The company is seeking a better year in 2020 — turning to a strategy of leasing the systems to major hospitals in order to increase adoption. The company is also looking to package more artificial intelligence features in the Senhance system.
